10-Q: Charlotte's Web Reports Revenue Decline, Net Loss

Charlotte's Web Holdings, Inc. reported a 15.2% decrease in revenue for the three months ended June 30, 2026, alongside a net loss of $4.1 million.

Summary

• Charlotte's Web Holdings, Inc. reported a net loss of $4.13 million for the three months ended June 30, 2026, compared to a net loss of $6.29 million in the same period last year.
• Total revenue for the three months ended June 30, 2026, was $10.86 million, a decrease of 15.2% from $12.81 million in the prior year period.
• The company experienced a significant loss of $4.22 million from the extinguishment of debt related to the conversion of its convertible debenture.
• As of June 30, 2026, the company had $13.99 million in cash and cash equivalents.
• The company completed a transaction with BT DE Investments Inc. (BAT) on May 28, 2026, involving the conversion of a convertible debenture and an additional equity investment, resulting in BAT holding approximately 40.6% of the company's shares.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to declining revenues, increased net losses, and a significant loss from debt extinguishment, despite some strategic shifts and a capital infusion.

Positives

• Gross margin improved to 47.5% from 46.8% for the three months ended June 30, 2026, due to an improved product and channel mix.
• Selling, general, and administrative expenses decreased by 5.4% for the three months ended June 30, 2026, reflecting cost-cutting measures.
• Net cash used in operating activities decreased to $3.71 million for the six months ended June 30, 2026, from $6.79 million in the prior year period, indicating improved operational efficiency.
• The company received $10 million in proceeds from the issuance of common stock related to the conversion of its convertible debenture and accrued interest.

Negatives

• Total revenue for the three months ended June 30, 2026, decreased by 15.2% to $10.86 million compared to $12.81 million in the same period last year.
• Total revenue for the six months ended June 30, 2026, decreased by 12.2% to $22.01 million compared to $25.07 million in the same period last year.
• The company reported a net loss of $4.13 million for the three months ended June 30, 2026, and $17.24 million for the six months ended June 30, 2026.
• A significant loss of $4.22 million was recognized from the extinguishment of debt due to the conversion of the convertible debenture.
• Gross margin declined to 47.1% for the six months ended June 30, 2026, from 48.7% in the prior year period.

Risks

• The company's ability to fund its operations for the longer term depends on future operating performance, revenue growth, and expense management, which can be affected by general economic conditions, industry regulatory changes, and other factors beyond its control.
• New state regulations may impact the company's ability to sell certain products as currently formulated or packaged, requiring adjustments to product formulation, labeling, and incurring additional costs.
• The company's investment in DeFloria involves estimation uncertainty due to the use of subjective assumptions and unobservable inputs (Level 3) for fair value determination.
• The company's financial results are subject to the fair value fluctuations of financial instruments, including debt conversion options and interest rate conversion features.

Future Outlook

The company expects a continued cost containment strategy in overall selling, general, and administrative expenses in 2026. Management believes existing cash and cash equivalents will provide sufficient liquidity for the next 12 months. Longer-term funding depends on future operating performance, revenue growth, and expense management, and may involve fundraising through borrowings or equity/debt issuances.

Management Comments

• Management believes that the Company's existing cash and cash equivalents, and short-term investments will provide sufficient liquidity to fund operations and planned capital expenditures for the next 12 months.
• The Company expects a continued cost containment strategy in overall selling, general, and administrative expenses in 2026 as a result of several actions taken over the prior two years.

Industry Context

StockSavvy.ai notes that Charlotte's Web's performance reflects ongoing challenges in the CBD and hemp wellness market, characterized by evolving regulations, increased competition, and a shift towards more diversified botanical wellness products. The company's strategic pivot towards minor cannabinoids, functional mushrooms, and hemp-derived THC, alongside efforts in clinical research and medical channels, aligns with broader industry trends seeking to expand product applications and market reach.

Comparison to Industry Standards

• The company's gross margin of 47.5% for the quarter is within a typical range for consumer packaged goods, but the decline in revenue suggests market pressures or strategic shifts impacting top-line growth.
• The significant loss from debt extinguishment is a one-time event but highlights the financial restructuring undertaken, which is common for companies in this sector navigating growth and capital needs.
• The company's focus on R&D and clinical trials for hemp-derived compounds is a strategy employed by other players in the wellness and pharmaceutical sectors to validate product efficacy and explore new therapeutic applications.

Legal Proceedings

• From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. Management believes that as of June 30, 2026, there is no litigation pending that could have, individually and in the aggregate, a material adverse effect on the Company's financial position, results of operations or cash flows.
• The Company is not a party to any material pending legal proceedings, other than ordinary routine litigation incidental to the business.
• The Company is not or its property the subject of any legal proceedings, known or contemplated, that involve a claim for damages exclusive of interest and costs that meet or exceed 10% of its current assets.

Related Party Transactions

• The Company has an accounts receivable balance due from DeFloria of $1,689 as of June 30, 2026.
• The Company entered into a consulting agreement with Jared Stanley, a former executive and current Board member, for a bi-weekly fee of $6.
• The Company has a supply agreement with DeFloria, charging at cost of goods sold level for raw materials.
• The Company has a service agreement with DeFloria, recognizing revenue and cost of goods sold for services provided.
• The Company loaned $750 to DeFloria on July 15, 2025, with a balance of $827 including accrued interest as of June 30, 2026.

Stakeholder Impact

• Shareholders may experience continued share price volatility due to revenue declines and net losses, although the capital infusion from BAT provides some stability.
• Creditors may be impacted by the company's ongoing need for liquidity and potential future fundraising activities.
• Employees may be affected by cost-cutting measures and workforce adjustments aimed at improving operating efficiency.
• Suppliers may see changes in order volumes due to the shift towards a distributor model and cost optimization efforts.

Next Steps

• Continue cost containment strategy in overall selling, general, and administrative expenses.
• Execute strategic growth plans, including product diversification and expansion into medical channels.
• Monitor and adapt to evolving state regulations impacting product sales.
• Utilize existing cash and cash equivalents to fund operations and planned capital expenditures for the next 12 months.
• Explore fundraising opportunities for longer-term liquidity requirements.

Key Dates

Recommendation

The company shows signs of strategic adaptation and cost control, evidenced by improved gross margins and reduced SG&A expenses. However, the persistent revenue decline, significant net losses, and the substantial loss from debt extinguishment present considerable headwinds. The recent capital infusion from BAT provides a necessary liquidity buffer and strategic partnership, but the path to sustained profitability remains uncertain given the challenging market conditions and regulatory landscape. A 'hold' recommendation reflects a cautious approach, awaiting clearer evidence of revenue stabilization and a return to profitability before considering a more positive stance.

Keywords

CBD, Hemp Extract, Wellness Products, Convertible Debenture, Financial Statements, Revenue, Net Loss, Regulatory Changes